GlassScriptPhysician profile
Leigh Aurora Keefer
NPI 1336426444
$4,520.64
in general payments reported to CMS, 2019-2025
24 companies · $277 in 2025
The $277 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $966 · 2022: $797 · 2023: $1,471 · 2024: $1,010 · 2025: $277.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,569 · Education: $189.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,569.18 |
| Education | $189.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $888.41 | 2021-2025 | Wegovy |
| Abbvie INC. | $880.69 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $823.64 | 2021-2025 | Farxiga, Breztri, Airsupra |
| Lilly USA, LLC | $366.51 | 2021-2025 | Zepbound, Jardiance, Mounjaro |
| Astellas Pharma US INC | $237.02 | 2023-2024 | Veozah |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $203.02 | 2023-2024 | Caplyta |
| Axsome Therapeutics, INC. | $196.08 | 2023-2024 | Auvelity |
| Biohaven Pharmaceutical Holding Company LTD. | $182.96 | 2022 | |
| Blueprint Medicines Corporation | $133.76 | 2023 | Ayvakit |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $116.71 | 2023-2024 | Xifaxan, Trulance |
| Pfizer INC. | $86.41 | 2023-2024 | |
| Daiichi Sankyo INC. | $72.08 | 2022-2024 | Injectafer |
| Biohaven Pharmaceuticals, INC. | $62.04 | 2021 | |
| Ibsa Pharma INC. | $61.04 | 2022-2023 | Tirosint, Licart |
| Qol Medical, LLC | $42.71 | 2023 | Sucraid |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pharmacosmos Therapeutics INC. | $24.26 | 2023 | Monoferric |
| Amarin Pharma, INC. | $24.17 | 2021 | |
| Supernus Pharmaceuticals, INC. | $21.87 | 2024 | Qelbree |
| Glaxosmithkline, LLC. | $18.75 | 2021 | |
| Sandoz INC. | $17.19 | 2023 | Hyrimoz |
| Antares Pharma, INC. | $16.32 | 2022 | |
| Merck Sharp & Dohme LLC | $15.31 | 2021 | |
| Eisai INC. | $15.29 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $14.40 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Leigh Keefer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.